Abstract
Background Relapsing-remitting multiple sclerosis (RRMS) involves autoimmune responses against central nervous system (CNS) self-epitopes, potentially triggered by Epstein–Barr virus (EBV) and Human Herpesvirus 6 (HHV-6) reactivation.
Objectives To evaluate IgG/IgA/IgM responses targeting the enteric nerve and non-myelin antigens in RRMS and investigate associations with EBV and HHV-6 markers and explore molecular mimicry between viral and host antigens.
Methods The study included 55 RRMS patients and 63 matched healthy controls. ELISA is used to examine IgG/IgA/IgM levels against nine non-myelin self-epitopes and viral proteins (EBNA-1, dUTPases of EBV and HHV-6). Luminex immunoassay is used to quantify cytokines, chemokines, and growth factors. Disability was evaluated using the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS). In-silico molecular mimicry was analyzed using UniProt, AlphaFold, PyMol, Alignmentaj, and the Immune Epitope Database (IEDB), comparing 41 viral and 36 ENS non-myelin antigens.
Results IgG/IgA/IgM levels targeting the enteric nerve and non-myelin antigens were significantly higher in RRMS than in controls. A large part of the variance in the EDSS and MSSS scores (>60%) was explained by IgG-chondroitin sulfate, IgM-Asialo-ganglioside, and IgG-enteric nerve. There were highly significant correlations between autoimmunity to those self-antigens and either immune profiles indicating immune activation or Ig-responses to EBNA-1, and EBV/HHV-6 DUTPases. Molecular mimicry analysis confirmed the association between EBV/HHV-6 and the self-antigens by identifying shared pentapeptides, which might cause T-cell immunogenicity.
Conclusion RRMS is characterized by autoimmune responses targeting the enteric nerve and non-myelin proteins. EBV and HHV-6 reactivation contribute via molecular mimicry mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AFA received funding for the project from the C2F program at Chulalongkorn University in Thailand, with grant number 64.310/436/2565. The Thailand Science Research, and Innovation Fund at Chulalongkorn University (HEA663000016) and the Sompoch Endowment Fund (Faculty of Medicine) MDCU (RA66/016) provided funding to MM. Immunosciences Lab., Inc., Los Angeles, CA, USA, and Cyrex Labs, LLC, Phoenix, AZ, USA, provided funding for the execution of all antibody assays.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the College of Medical Technology at the Islamic University of Najaf, Iraq, granted sanction for the investigation (Document No. 11/2021). Written informed consent was obtained from all patients and control participants, and all procedures were conducted in accordance with Iraqi and international ethical standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Joined first authorships
Data Availability
The corresponding author (MM) will grant access to the dataset supporting this study upon receipt of a valid request and the completion of a comprehensive data review.
